7 Related NICE guidance
-
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. NICE technology appraisal guidance 169 (2009).
-
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. NICE technology appraisal guidance 178 (2009).
-
Everolimus for the second-line treatment of advanced renal cell carcinoma.NICE technology appraisal guidance 219 (2011).